Clinical evidence in skincare supports regulatory defensibility, claim substantiation, and commercial credibility across Canada and the United States. As skincare products move across categories such as cosmetics, sunscreens, antiperspirants, antibacterial products, wound care, and oral skin health supplements, trial design, endpoint selection, and participant criteria become critical to how claims are supported and positioned in-market.
Introduction
Skincare has become an increasingly evidence-driven and commercially competitive category across Canada and the United States. As brands pursue stronger performance claims, broader market access, and greater scientific credibility, human clinical data has become central to claim substantiation, regulatory strategy, and product differentiation. Clinical evidence helps determine how skincare products are classified, how claims can be positioned, and whether products can move from formulation concept to compliant, defensible market entry.
This article examines how skincare clinical trials are designed, executed, and applied across key product categories, including cosmetics, sunscreens, antiperspirants, antibacterial products, wound care products, and oral skin health supplements. It explains how clinical endpoints are selected, how participant criteria and study design influence claim strength, and how evidence expectations differ across regulatory classifications in Canada and the United States.
For product development, regulatory affairs, marketing, and brand strategy teams, clinical evidence is no longer a technical afterthought. It is a practical requirement for building skincare products with claims that are scientifically credible, regulatorily defensible, and commercially meaningful. Through SNI Clinic’s clinical research capabilities, including study design support, participant recruitment, controlled product testing, data collection, and endpoint-driven claim support, skincare brands can better align clinical execution with regulatory and commercial objectives.
- What Are Skincare Clinical Trials and Why They Matter
- Purpose, Methodology, and Claim Substantiation in Skincare Research
- Regulatory and Commercial Purpose of Clinical Data
- Clinical Trials as a Competitive Advantage for Brands
- Types of Skincare Products Evaluated in Clinical Trials
- Key Clinical Endpoints Used to Substantiate Skincare Performance
- Hydration and Barrier Function
- Skin pH and Microbiome Safety
- Antibacterial Activity and Residual Effectiveness
- Antiperspirant Efficacy and Sweat Reduction
- Anti-Aging, Firmness, and Elasticityra
- Wrinkles, Texture, and Skin Surface Topography
- Hyperpigmentation and Tone Evenness
- Dark Circles and Under-Eye Puffiness
- How Skincare Clinical Trial Design and Participant Selection Impact Claim Substantiation
- Safety and Sensitivity Considerations in Trial Design
- The Role of Skincare Clinical Research Organizations (CROs)
- Final Remarks
- FAQ
What Are Skincare Clinical Trials and Why They Matter
Definition of Skincare Clinical Trials
Skincare clinical trials are structured human research studies designed to evaluate the safety, tolerability, and performance of topical products, transdermal systems, and products intended to impact skin structure, function, or appearance. These trials translate laboratory formulation data into in vivo evidence by measuring biological responses under controlled conditions of use.
Depending on product classification and intended claims, skincare trials may range from cosmetic safety and instrumental efficacy studies to formal drug or device investigations conducted under Good Clinical Practice (GCP). Across all categories, the defining feature of a skincare clinical trial is the generation of objective, human-based data under a documented protocol with predefined endpoints and statistical methodology.
Why Human Data Is Essential for Safety, Performance, and Claims
In vitro models, cell cultures, and bench testing provide valuable early information on ingredient behaviour, but they cannot replicate the complexity of living human skin. Human clinical data are required to confirm safety and to quantify biological performance under realistic conditions of use.
Key endpoints such as stratum corneum hydration, transepidermal water loss, viscoelastic properties, pigmentation, erythema, microbial activity, sweat production, and comedone formation can only be meaningfully assessed in vivo. These parameters are measured using validated biophysical instrumentation and standardized clinical grading scales. Protocol-defined inclusion and exclusion criteria, controlled application regimens, and pre-specified statistical analysis plans ensure that observed effects are attributable to the product itself rather than external confounding factors and mere chance.
How Clinical Trials Support Regulatory Compliance and Marketing Credibility
Clinical trial data form the evidentiary foundation for regulatory defensibility and truthful advertising, which is a baseline requirement for product marketing across regulated markets. In both Canada and the United States, objective performance and safety claims on skincare products must be supported by adequate and proper clinical research and testing to withstand regulatory, legal, and competitive scrutiny.
Clinical outcomes directly define the permissible scope and precision of cosmetics claims, including claims related to moisturization, barrier support, firming, wrinkle reduction, hyperpigmentation, antibacterial activity, antiperspirant performance, photoprotection, and wound support.
Beyond compliance, well-designed clinical trials elevate marketing credibility by enabling brands to communicate quantified, verifiable results The alignment between science, regulation, and communication is what converts clinical evidence into a durable commercial advantage.
Purpose, Methodology, and Claim Substantiation in Skincare Research
Scientific Purpose of Clinical Studies
The scientific purpose of skincare clinical studies is to objectively characterize how a product interacts with human skin under controlled conditions of use. Clinical trials are designed to quantify biological responses using validated biophysical, microbiological, and imaging-based endpoints.
Parameters such as stratum corneum hydration, transepidermal water loss, viscoelastic properties, pigmentation, erythema, microbial activity, sweat production, and comedone formation are measured to establish both mechanistic effect and clinical relevance. Rigorous and effective clinical methodology requires pre-defined protocols, clearly defined primary and secondary endpoints, controlled exposure conditions, and pre-specified statistical analysis plans to ensure that observed effects are reproducible, unbiased, and biologically meaningful.
Regulatory and Commercial Purpose of Clinical Data
Clinical Data Supports Cosmetic Safety and Regulatory Responsibility
From a regulatory perspective, clinical data play a critical role in demonstrating that cosmetic products are safe under labelled and customary conditions of use. In both Canada and the United States, manufacturers and distributors are legally responsible for ensuring that cosmetics are not unsafe, adulterated, or misbranded, and that they are safe under normal and reasonably foreseeable conditions of use. While regulators do not typically mandate specific test methods, they expect companies to apply whatever testing is scientifically necessary to substantiate safety, including human tolerability studies, where appropriate.
Higher-Risk Ingredients and Stronger Claims Require Stronger Evidence
Controlled human testing becomes particularly important when either a new ingredient is introduced or when claims extend beyond generally acceptable cosmetic positioning. New ingredients, delivery systems, or higher active concentrations often lack safety history, making human testing essential. Likewise, claims that move beyond basic appearance language into quantified, time-bound, functional, or physiological territory, such as sensitive skin, barrier repair, antibacterial, clinical-strength antiperspirant, post-procedure recovery, or microbiome protection, significantly elevate both regulatory scrutiny and risk exposure. In these scenarios, clinical evidence shifts from supportive to essential for regulatory defensibility.
Clinical Evidence Strengthens Post-Market Risk Management and Commercial Confidence
Clinical evidence also plays a critical role in post-market cosmetic risk management and change control. When consumer complaints, irritation trends, or safety inquiries arise, baseline clinical data provide the comparator needed to evaluate whether reactions fall within expected use variability or represent a true safety signal. Similarly, formulation updates, fragrance changes, preservative substitutions, or packaging-material modifications may warrant renewed safety assessment, including targeted clinical testing, to prevent regulatory concern, retailer hesitation, or market withdrawal. From a commercial standpoint, the same data strengthen packaging, digital marketing, professional education, and retailer confidence, while also supporting buyer due diligence, professional endorsement, and brand valuation discussions as a strategic commercial asset.
Clinical Trials as a Competitive Advantage for Brands
When strategically designed, skincare clinical trials move beyond compliance to become a primary driver of market differentiation. High-quality human data reduce formulation and launch risk, strengthen regulatory positioning, and materially elevate the credibility of performance claims with dermatologists, retailers, and increasingly informed consumers.
In categories crowded with ingredient-based and theoretical positioning, clinically substantiated outcomes allow brands to demonstrate quantified performance under controlled conditions of use. This conversion of marketing narrative into verified scientific evidence supports premium pricing, accelerates retail acceptance, and builds durable brand equity across jurisdictions.
Types of Skincare Products Evaluated in Clinical Trials
Cosmetics and Personal Care Products
Cosmetic and personal care products represent the largest category of skincare items evaluated in clinical trials. This includes moisturizers, cleansers, serums, toners, masks, exfoliants, eye creams, and body care products. Clinical studies for cosmetics primarily focus on safety, tolerability, instrumental efficacy, and consumer perception. Endpoints commonly include hydration, transepidermal water loss, elasticity, wrinkle appearance, pigmentation, erythema, comedogenicity, and skin feel. Although, in most cases, cosmetics do not undergo a pre-market assessment by regulators in either Canada or the United States, objective human data are essential to support claims and to meet advertising and legal obligations.
Sunscreens and Photoprotection Products
Sunscreens and photoprotection products are subject to more stringent evidentiary and regulatory requirements than most standard cosmetics because they perform a UV-protective, health-related function.
In Canada, sunscreens are regulated as non-prescription drugs or NHPs depending on the active UV filters and the overall formulation, this includes determining whether the filters align with an applicable monographs (where applicable).
In the United States, sunscreen products are regulated as over-the-counter (OTC) drugs, and their active UV filters must either conform to the FDA sunscreen monograph or proceed through a non-monograph pathway, such as a New Drug Application (NDA) or an Over-the-Counter Monograph Order Request (OMOR), if they do not meet the monograph parameters.
Regulatory-compliant evaluation typically includes:
- in vivo SPF (UVB) testing
- in vitro or in vivo UVA protection assessment for broad-spectrum designation
- Photostability testing
- Water- or sweat-resistance testing.
Data from these studies are required to substantiate SPF values, broad-spectrum protection, and durability claims on product labels.
Although these required sunscreen evaluations involve controlled human testing, they are performance and safety tests rather than full exploratory clinical trials in the pharmaceutical sense.
A formal clinical trial becomes necessary only when a sunscreen falls outside existing monograph frameworks, incorporates novel UV filters, or makes expanded therapeutic or non-standard claims, such as disease prevention, DNA damage protection, post-procedure use, or enhanced phototoxicity safety positioning. In these cases, additional population-specific safety, efficacy, and sometimes long-term exposure studies may be required. As a result, the depth of clinical evidence for sunscreens is directly driven by both regulatory classification and the ambition of the intended claims.
Antiperspirants and Deodorants
Antiperspirants and deodorants are evaluated using human clinical models designed to assess objective sweat reduction, odour control, and skin tolerability.
Antiperspirant efficacy is most commonly quantified using gravimetric sweat measurement under controlled stimulation conditions, with results expressed as percentage reduction relative to baseline or placebo.
Deodorant and combination antiperspirant-deodorant products may also undergo microbiological assays to assess reductions in odour-causing bacteria, alongside sensory panel odour scoring and formal skin compatibility evaluation. Regulatory classification, and therefore the level of required clinical evidence, depends on jurisdiction and intended claims.
For example, in the United States antiperspirants are regulated as OTCs whereas, in Canada, many aluminum-based antiperspirants are regulated as cosmetics, unless they are labelled with hyperhidrosis or therapeutic related claims. As a result, the rigour of evidence generation and clinical trial design is calibrated to reflect both regulatory expectations and recognized clinical best practices.
Antibacterial Skin Products
Antibacterial skincare products include hand washes, sanitizers, body cleansers, and leave-on formulations represented to reduce microbial load on the skin.
Clinical evaluation for such products focuses on immediate antibacterial activity, typically expressed as log reductions in bacterial counts, as well as residual effectiveness and substantivity over time. Additional safety endpoints assess irritation, sensitization, and suitability for repeated daily use.
Because antibacterial claims imply a health-related effect, these products often sit at the cosmetic-drug interface, making clinical substantiation particularly important for regulatory defensibility and advertising compliance.
Wound Care Products and Dressings
Wound care products include films, foams, hydrocolloids, adhesives, tapes, gauzes, and topical wound treatments intended for use on compromised or healing skin.
Unlike most standard skincare products, these products are not regulated as cosmetics when represented for the management, protection, or treatment of wounds.
In both Canada and the United States, the majority of wound dressings and advanced topical wound products are regulated as medical devices, meaning their clinical performance must align with device classification, intended use, and associated risk profile.
Clinical evaluation in this category therefore focuses on both functional performance and safety, with endpoints commonly including adhesion, periwound erythema, exudate management, moisture balance, skin barrier protection and recovery, pain on removal, and healing progression over time. As a result, well-designed human studies are essential to demonstrate not only mechanical and protective function, but also patient tolerability, safety during repeated or extended wear, and suitability for use on compromised skin.
Skin Health Supplements
Skin health supplements are formulated to support claims related to skin hydration, elasticity, barrier function, pigmentation, acne, and overall skin appearance through systemic mechanisms rather than topical action. These products are not regulated as cosmetics in either Canada or the United States because they are intended for oral consumption and exert their effects internally.
In Canada, they are typically regulated as NHPs under the Natural Health Products Regulations (NHPR), while in the United States they fall under dietary supplement regulation pursuant to the Dietary Supplement Health and Education Act (DSHEA).
Clinical trials in this category focus on systemic effects on the skin, using endpoints such as hydration, wrinkle depth, sebum production, inflammatory biomarkers, and pigmentation metrics. Although these products do not act directly on the skin surface, well-designed human clinical data remain essential to substantiate structure-function and appearance-related claims in a compliant, defensible manner for both regulatory and marketing purposes.
Key Clinical Endpoints Used to Substantiate Skincare Performance
Skincare efficacy claims are supported through a structured set of validated clinical endpoints that quantify how products affect skin parameters such as hydration, barrier integrity, microbial control, pigmentation, aging, and sweat production. Rather than relying on a single test, modern clinical programs apply a suite of complementary measurements to ensure that both immediate cosmetic effects and longer-term biological responses are accurately captured. The most common endpoint categories include the following:
Hydration and Barrier Function
Assessed using corneometry, tewametry (transepidermal water loss), and barrier recovery models to support claims such as hydrates, moisturizes, barrier repair, reduces moisture loss, and restores compromised skin.
Skin pH and Microbiome Safety
Surface pH measurement and microbiome stability testing support pH balanced, microbiome safe, gentle cleansing, and sensitive-skin claims.
Antibacterial Activity and Residual Effectiveness
Immediate log reduction testing and residual substantivity models support antibacterial and extended protection claims.
Antiperspirant Efficacy and Sweat Reduction
Gravimetric sweat testing and percentage reduction analysis support antiperspirant and clinical strength sweat-control claims.
Anti-Aging, Firmness, and Elasticity
Cutometry, high-frequency ultrasound (MHz ecography), and mechanical response testing quantify dermal thickness, density, and viscoelastic improvements supporting firming, tightening, and resilience claims.
Wrinkles, Texture, and Skin Surface Topography
3D profilometry and standardized digital imaging objectively measure wrinkle depth, roughness, and surface texture changes.
Hyperpigmentation and Tone Evenness
Melanin index and colourimetric analysis support brightening, dark spot reduction, and tone-correcting claims.
Dark Circles and Under-Eye Puffiness
Periorbital imaging and volumetric analysis quantify changes in pigmentation, shadowing, and tissue swelling in the eye contour area.
In practice, a modern cosmetic clinical program rarely relies on a single outcome measure. Robust evidence generation typically integrates biophysical efficacy endpoints, functional safety assessment, sensory tolerability, and consumer perception within a unified study design. How these layers of data are generated, and in which populations, directly determines the strength, scope, and defensibility of the resulting claims.
How Skincare Clinical Trial Design and Participant Selection Impact Claim Substantiation
Study Design and Participant Selection
Study design and participant selection directly determine the scientific validity and regulatory defensibility of skincare clinical trial outcomes.
A well-chosen study model ensures that observed effects can be attributed to the investigational product itself rather than to variability in skin biology, user behaviour, or environmental exposure. Regulatory agencies, advertising review bodies, and expert peer reviewers all assess study design quality when evaluating whether clinical data are reliable enough to support product claims.
Beyond scientific rigour, study design also influences feasibility, statistical sensitivity, cost, recruitment complexity, and market relevance. Model selection must therefore balance methodological control with real-world use conditions, the intended claim strength, and the characteristics of the target consumer population.
Randomized Controlled Designs
Randomized controlled designs remain the gold standard for skincare efficacy studies because they minimize selection bias and distribute both known and unknown confounders evenly across treatment groups. Participants are randomly assigned to receive either the test product, an active comparator, or a control, ensuring that observed differences in outcomes are statistically attributable to the product itself. Randomization is typically computer-generated and fixed prior to study initiation as specified in the statistical analysis plan.
These designs are most commonly applied to high-impact or higher-risk claims, including anti-aging, pigmentation reduction, antiperspirant efficacy, antibacterial activity, and barrier repair, where human evidence is required to demonstrate true biological effect. Because randomized controlled designs allow for direct between-group statistical comparisons and minimize bias, they are widely regarded as the most scientifically defensible study framework for these claim categories. As a result, RCT-generated data carry significant weight with regulators, retailers, and advertising review bodies when evaluating the credibility and reliability of performance claims.
While randomized controlled trials are not universally mandated for all cosmetic or skincare claims, they provide the highest level of protection against regulatory scrutiny, advertising challenges, and legal dispute when claims approach therapeutic, functional, or health-related territory. In practice, brands pursuing stronger, more specific, or more competitive claims often select randomized controlled designs to ensure their evidence package meets the highest standards of scientific defensibility.
Split-Face and Split-Body Application Models
Split-face and split-body designs use the same participant as both test and control, with different products applied to contralateral anatomical sites. This approach reduces inter-individual variability and increases statistical sensitivity with smaller sample sizes by controlling for genetic, lifestyle, and environmental factors within each participant. These models are especially well suited for facial skincare, pigmentation, anti-aging, acne, and barrier studies where bilateral symmetry allows for precise intra-participant comparisons.
They are most commonly applied during early-stage development and comparator screening, where rapid signal detection is required. However, because of migration risk, compliance sensitivity, and limited applicability for whole-body indications, these designs are generally considered supportive rather than primary evidence for regulated claim categories such as SPF, antiperspirant, antibacterial, and wound care.
Parallel-Group Comparator Studies
Parallel-group designs assign separate groups of participants to different products or controls over the same study period. This model is required when a split-site application is impractical due to product format, application logistics, or full-body exposure, such as with cleansers, sunscreens, antiperspirants, ingestible supplements, and whole-body treatments.
These studies are particularly suited to longer-duration investigations where cumulative effects, delayed onset of action, tolerability trends, and real-world usage behaviour must be captured. Because biological variability between participants is higher than in split-site models, larger sample sizes are typically required to achieve appropriate statistical power.
Vehicle-Controlled Benchmarks
Vehicle-controlled studies compare the full formulation against its identical base without the functional active. This design isolates the true contribution of the active ingredient by controlling for the moisturizing, sensory, or barrier effects of the vehicle itself.
Vehicle controls are essential for substantiating ingredient-specific claims associated with retinoids, exfoliating acids, depigmenting agents, peptides, microbiome actives, and antibacterial compounds. Without this control, causal attribution becomes ambiguous, weakening both scientific interpretation and regulatory defensibility.
Participant Inclusion Criteria
Inclusion criteria define the population to whom claims can be legitimately applied. Typical parameters include age ranges aligned with positioning, Fitzpatrick skin phototypes I to VI, presence of the target condition such as acne, hyperpigmentation, sensitive skin, barrier impairment, or hyperhidrosis, and minimum baseline severity thresholds defined using validated grading systems.
Claims cannot be generalized beyond the studied population. Data generated in mild acne populations cannot support moderate-to-severe acne claims, and adult-only studies cannot be extrapolated to paediatric users without additional supporting evidence. Properly constructed inclusion criteria therefore determine both the scientific relevance and the legal scope of claim application.
Exclusion Criteria and Confounding Factors
Exclusion criteria remove variables that could distort outcomes or compromise participant safety. Common exclusions include recent use of retinoids, corticosteroids, antibiotics, exfoliating procedures, lasers, chemical peels, active dermatologic disease unrelated to the indication being studied, and medications known to alter skin physiology or sweat production.
Failure to adequately control confounders is one of the most common reasons clinical data fail regulatory, advertising, or legal scrutiny. From a scientific standpoint, strong exclusion criteria protect internal validity. From a commercial standpoint, they protect brands from claim challenges, complaint escalation, and the need for costly trial repetition.
Safety and Sensitivity Considerations in Trial Design
Safety and sensitivity assessment should be built into skincare clinical trial design from the earliest protocol development stage.
Safe study design must consider formulation type, active ingredient profile, frequency and duration of use, intended anatomical site, target population, and regulatory classification to determine the appropriate level of topical safety testing. Products intended for daily use, extended wear, use on compromised or post-procedure skin, acne-prone populations, paediatric users, or long-term leave-on exposure generally require a higher safety evidence threshold than short-contact or rinse-off formulations used on intact skin.
From a clinical trial design standpoint, safety testing must address both immediate exposure risk and cumulative biological impact over time. These considerations influence inclusion and exclusion criteria, exposure regimens, visit schedules, endpoint selection, and the structure of adverse event monitoring and stopping rules. The objective is to demonstrate that product performance is achieved without compromising skin integrity, tolerability, or long-term skin health under realistic conditions of use.
In modern skincare research, safety and sensitivity endpoints are not isolated add-ons but are strategically integrated into efficacy protocols. A well-designed clinical program typically layers acute irritation, cumulative irritation, comedogenicity, mildness, and, where appropriate, Human Repeat Insult Patch Testing (HRIPT) into a phased evidence-generation strategy that mirrors real-world use patterns and risk profiles.
The Role of Skincare Clinical Research Organizations (CROs)
Skincare Clinical Research Organizations, or CROs, help brands turn product concepts into clinically substantiated evidence that can support safety, performance, and claim defensibility. By aligning study design, endpoints, participant criteria, data collection, and regulatory expectations, CROs help ensure that clinical testing supports what brands intend to communicate in-market.
CROs also support trial execution, data integrity, adverse event tracking, and the translation of study results into compliant claim language for packaging, websites, advertising, retailer submissions, and professional education. This reduces over-claiming risk and strengthens regulatory, commercial, and due diligence readiness.
In evidence-driven skincare markets, well-designed CRO-led studies can improve retailer confidence, professional trust, cross-border positioning, and long-term brand differentiation.
Final Remarks
Skincare clinical trials are no longer optional technical exercises reserved for high-risk or drug-class products. They now serve as the primary mechanism through which formulation intent is converted into substantiated performance, regulatory compliance, and market credibility. From hydration and microbiome safety through to antiperspirant efficacy, photoprotection, antibacterial substantivity, and wound healing, modern clinical programs integrate biophysical instrumentation, microbiological models, advanced imaging, and structured statistical analysis to generate real-world proof of function.
As regulatory oversight intensifies and retailers, dermatologists, and consumers demand verifiable performance, the quality of clinical evidence increasingly determines a product’s ability to succeed across premium, professional, and regulated retail channels. Well-designed clinical studies reduce launch risk, support precise claim language, enable cross-border expansion, and provide the scientific foundation for durable brand equity.
When science, regulatory strategy, and commercial objectives are aligned from the earliest stages of development, brands move beyond assumption-based marketing and into evidence-led growth. In today’s skincare landscape, demonstrating what a product does is no longer a competitive advantage. It is the baseline expectation for long-term success.
As product technologies evolve and regulatory expectations continue to rise, PK/PD evidence has become essential rather than optional. Applying these principles early strengthens development decisions, reduces uncertainty, and supports predictable, defensible pathways to approval.
SNI Clinic: Supporting Skincare Clinical Trials and Claim Substantiation
SNI Clinic supports skincare brands with clinical research services that help substantiate product claims, strengthen regulatory defensibility, and support market credibility in Canada and the United States. Our capabilities include study design support, participant recruitment, controlled product testing, endpoint selection, data collection, and claim-focused reporting.
SNI Clinic works with brands developing cosmetics, sunscreens, antiperspirants, deodorants, antibacterial skin products, wound care products, and oral skin health supplements. By aligning study design with intended claims, product classification, participant criteria, and measurable endpoints, we help generate human clinical data that can support packaging claims, website language, retailer submissions, professional education, and broader commercial positioning.
Whether you are evaluating hydration, barrier function, irritation, sensitivity, pigmentation, elasticity, sweat reduction, odour control, antibacterial activity, or other skincare performance outcomes, SNI Clinic helps translate controlled clinical testing into credible, defensible evidence that supports compliant market entry and stronger brand positioning.
Send us a request for an introductory call using the form below!
FAQ
Do skincare products legally require clinical trials in Canada and the United States?
Cosmetic skincare products do not generally require a specific type of clinical trial in Canada or the United States. However, companies are legally responsible for ensuring that products are safe under labelled and customary conditions of use, and that claims are truthful, supportable, and not misleading. Clinical testing becomes more important when a product presents higher safety considerations, uses novel ingredients, or makes claims that go beyond basic cosmetic positioning.
When is clinical testing recommended for skincare products?
Clinical testing is recommended when skincare products involve new ingredients, novel delivery systems, sensitive-skin positioning, periocular use, paediatric use, compromised-skin use, or long-term daily leave-on exposure. It is also strongly recommended when claims imply measurable functional or biological performance, such as barrier support, reduced transepidermal water loss (TEWL), antibacterial activity, uneven tone improvement, depigmentation, sweat reduction, post-procedure recovery, or microbiome-related benefits.
What is the difference between cosmetic testing and a clinical trial?
Cosmetic testing typically evaluates product performance through controlled use studies, consumer perception studies, or non-invasive instrumental measurements such as hydration, transepidermal water loss (TEWL), elasticity, sebum, erythema, pigmentation, or wrinkle appearance. A clinical trial generally uses a more structured protocol, predefined endpoints, statistical analysis, safety monitoring, and stricter study controls. Depending on the product classification and claims, the study may also need to align with drug, natural health product, medical device, or other applicable research expectations.
Can one skincare clinical study support claims in both Canada and the United States?
Yes, a well-designed skincare clinical study can often support claim substantiation and marketing activities in both Canada and the United States. To be useful across markets, the study should use appropriate methodology, a representative participant population, validated or scientifically justified endpoints, clear inclusion and exclusion criteria, and claims that are directly supported by the data. Cross-market study planning can reduce duplicative testing, support consistent claim language, and strengthen regulatory defensibility.
How do skincare clinical research organizations support claim substantiation?
A skincare clinical research organization supports claim substantiation by aligning study design, endpoints, participant criteria, product use conditions, and data collection with the intended claims. For skincare brands, this helps ensure that clinical results can be translated into compliant packaging, website, advertising, retailer, and professional education language. Properly designed clinical testing can reduce over-claiming risk, support regulatory due diligence, and strengthen retailer, professional, investor, and consumer confidence.
✷ The content on this website, including information presented in this post, is provided for general informational purposes only and does not constitute legal, regulatory, or professional advice. While efforts are made to ensure accuracy, laws and regulations vary by jurisdiction and may change over time. Readers should not rely on this information as a substitute for advice from qualified legal or regulatory professionals. We disclaim any liability for actions taken based on this content, and users are encouraged to seek guidance specific to their circumstances.
